Menu
Log in
Log in

MEMBER LOGIN

Research | Data

Chicago Asthma Consortium participates in research, promotes existing asthma research studies, and encourages further investment into researching the causes, treatment and management of asthma. CAC also links the community to asthma research and links asthma researchers to the community through its Community Advisory Board and other community partners.



All Research & Data

<< First  < Prev   1   2   Next >  Last >> 
  • Thu, February 27, 2025 1:50 PM | Anonymous

    Self-reported food allergies (FAs) affect approximately 8% of the US pediatric and approximately 10% of the adult population, which reflects potentially disproportionate increases among ethnically and racially minoritized groups. Multiple gaps and unmet needs exist regarding FA disparities. There is reported evidence of disparities in FA outcomes, and the FA burden may also be disproportionate in low-income families. Low family income has been associated with higher emergency care spending and insecure access to allergen-free food. Pharmacoinequity arises in part as a result of structural racism still experienced by historically marginalized populations today. Historically redlined communities continue to experience greater rates of neighborhood-level air pollution and indoor allergen exposure, lack of transportation to medical appointments, poverty, and lower prescription rates of necessary medications. Clinical research needs racially and ethnically diverse participation to ensure generalizability of research findings and equitable access to medical advances, but race reporting in clinical trials has been historically poor. Addressing health disparities in FA is a priority of clinical care, with professional organizations such as the American Academy of Allergy, Asthma & Immunology having a prominent role to play in mitigating the challenges faced by these individuals. In this position statement we recommend some key steps to address this important issue.

    https://www.jacionline.org/article/S0091-6749(24)01065-0/fulltext

  • Tue, February 11, 2025 8:00 AM | Anonymous

    Findings from the 2017-2021 Medicare Current Beneficiary Surveys (MCBS)

    Recent national data indicates that 8% of adults ages 18 and older in the United States have current asthma (Centers for Disease Control and Prevention, 2023). However, those rates vary based on sex, race, ethnicity, and age. Among U.S. adults, asthma is more prevalent in females (9.7%) compared to males (6.2%). In terms of race and ethnicity, asthma is most prevalent in non-Hispanic American Indian/Alaskan Natives (13.3%), followed by non-Hispanic Blacks (10.7%), and non-Hispanic Whites (8.0%). It is least prevalent among Hispanics (6.7%) and non-Hispanic Asians (4.2%).

    When looking more specifically at older adults (ages 65 and older), 7.2% have current asthma nationally, accounting for approximately 20% of individuals with asthma in the United States (Centers for Disease Control and Prevention, 2023). However, asthma prevalence is likely higher among older adults, as it is widely understood to be underdiagnosed in the older population (Gibson et al., 2010). This is attributed to a combination of factors unique to older adults, including changes in lung structure and function (Dunn et al., 2017), challenges administering and interpreting pulmonary functioning tests used for diagnosis (Battaglia et al., 2016), an increase in comorbidities such as chronic obstructive pulmonary disease (COPD) (Tzortzaki et al., 2011), and complications related to polypharmacy (Battaglia et al., 2016). Additionally, asthma tends to be less controlled in older adults when compared to younger age groups, and mortality rates tend to be higher (Tsai et al., 2012; Talreja & Baptist, 2011). For example, asthma mortality rates in 2021 increased throughout the lifespan, with rates as low as 1.4 per million among those 0-4 years old, 2.4 per million among those 5-11, 2.0 per million among those 12-17, 3.8 per million among those 18-24, 6.4 per million among those 25-34, 11.5 per million among those 35-64, and 27.1 per million among those 65 and older (Centers for Disease Control and Prevention, 2023). The underdiagnoses, in conjunction with high mortality rates and a lack of literature on the disease among older adults, indicate a need for further investigation.

    https://publish.illinois.edu/geigerevallab/medicare-current-beneficiary-survey-mcbs/


  • Fri, October 25, 2024 12:01 PM | Anonymous

    For children with asthma, access to quick-relief medications is critical to minimizing morbidity and mortality. An innovative and practical approach to ensure access at school is to maintain a supply of stock albuterol that can be used by any student who experiences respiratory distress. To make this possible, state laws allowing for stock albuterol are needed to improve medication access.

    https://web.archive.org/web/20240420124321/https://www.atsjournals.org/doi/10.1164/rccm.202106-1550ST

  • Fri, October 25, 2024 11:59 AM | Anonymous

    Treatments for long-term control of asthma have improved and include a promising but expensive class of biologic therapies. However, the clinical trials evaluating these and other novel treatments have used a variety of different outcomes to evaluate efficacy. The evolution of asthma care calls for a re-examination of outcomes that are most important to patients and other stakeholders.

    https://www.annallergy.org/article/S1081-1206(21)00256-8/abstract

  • Fri, October 25, 2024 11:57 AM | Anonymous

    Severe asthma is a subtype of asthma that can be hard to control, resulting in an exceptional impact on an individual's quality of life. The aim of this review article is to explore the misalignment of perceptions of severe asthma among different stakeholders to identify how to reduce burden and improve delivery of care.

    https://www.worldallergyorganizationjournal.org/article/S1939-4551(20)30403-8/fulltext

  • Fri, October 25, 2024 11:55 AM | Anonymous

    Severe asthma is a debilitating, life-threatening disease associated with substantial global morbidity, mortality, and health care resource utilization. Patients may not receive guideline-directed medical care for severe asthma. Moreover, viable precision-based assessment tools and newer preventive therapies that can reduce the frequency of exacerbations and associated functional impact are underused. As a result, high rates of poorly controlled severe asthma persist, and patient health-related quality of life suffers.

    https://link.springer.com/article/10.1007/s12325-020-01450-7

  • Fri, October 25, 2024 11:48 AM | Anonymous

    Hispanic/Latinx (HL) ethnicity incorporates many subgroups from diverse racial and cultural backgrounds. Studies suggest that Puerto Ricans (PR) have a greater asthma prevalence and asthma-related morbidity relative to White and Mexican counterparts. However, these studies were in children or limited in clinical and phenotypic characterization. Our purpose was to determine whether clinical, phenotypic differences, and disparities in asthma-related morbidity exist across adult HL subgroups. Considering the shared heritage between PR and other Caribbean HL (Cubans and Dominicans, C&D), we hypothesized that Caribbean HL (CHL; PR and C&D) adults would have greater asthma morbidity compared to other HLs (OHL; Mexicans, Spaniards, Central/South Americans).

    https://journal.chestnet.org/article/S0012-3692(21)01523-3/fulltext


  • Fri, October 25, 2024 11:47 AM | Anonymous

    Little is known about how patients with asthma and eczema perceive their medical care and burden of disease. A survey was conducted to evaluate the perceptions among the general patient population with asthma and/or eczema regarding disease and treatment burden and barriers to adequate care.

    https://link.springer.com/article/10.1007/s12325-021-02021-0


  • Fri, October 25, 2024 11:45 AM | Anonymous

    Background

    In response to racial inequity in asthma, asthma-related research among diverse patients is vital. However, people from historically marginalized groups are underrepresented in clinical and patient-centered outcomes research (PCOR). The “Black People Like Me” (BPLM) virtual conference series was developed to: (1) engage Black patients with asthma and their caregivers in education and discussions about asthma, and (2) encourage involvement in PCOR. Education about COVID-19 and COVID-19 vaccination was also incorporated.

    https://researchinvolvement.biomedcentral.com/articles/10.1186/s40900-023-00428-3


  • Fri, October 25, 2024 11:40 AM | Anonymous

    Background

    Many patients have uncontrolled asthma despite available treatments. Most of the new asthma therapies have focused on type 2 (T2) inflammation, leaving an unmet need for innovative research into mechanisms of asthma beyond T2 and immunity. An international group of investigators developed the International Collaborative Asthma Network (ICAN) with the goal of sharing innovative research on disease mechanisms, developing new technologies and therapies, organising pilot studies and engaging early-stage career investigators from across the world. This report describes the purpose, development and outcomes of the first ICAN forum.

    https://publications.ersnet.org/content/erjor/9/3/00090-2023

<< First  < Prev   1   2   Next >  Last >> 


CHICAGO ASTHMA CONSORTIUM
400 E. Randolph St., Suite 3115, Chicago, IL 60601
Phone: 888-268-8334 Fax: 312-540-9900

Information contained on this website is provided with the understanding that Chicago Asthma Consortium, this site and its services, including all of the resources provided, serve informational purposes only. Only a doctor who is treating you can provide you with medical advice, examination, diagnosis or treatment. If you think you may have a medical emergency, call your doctor or 911 immediately. The Chicago Asthma Consortium does not endorse any medical or professional services referred to on this site or any links to this site. It also does not recommend or endorse any specific tests, products, procedures, opinions, or any other information that may be mentioned. While we try to keep the information on this site accurate, we cannot guarantee its accuracy, timeliness or completeness.

© 2025 Chicago Asthma Consortium

Powered by Wild Apricot Membership Software